vs
J.Jill, Inc.（JILL）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是J.Jill, Inc.的1.4倍（$207.3M vs $150.5M），J.Jill, Inc.净利率更高（6.1% vs -62.0%，领先68.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -0.5%），J.Jill, Inc.自由现金流更多（$16.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 0.1%）
J.Jill是1955年创立于美国马萨诸塞州的女装零售品牌，总部位于马萨诸塞州昆西市，自2017年起公开上市，主打面向女性消费者的服饰产品，在美国本土拥有稳定的线下销售网络与客群基础。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
JILL vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $150.5M | $207.3M |
| 净利润 | $9.2M | $-128.6M |
| 毛利率 | 70.9% | — |
| 营业利润率 | 9.9% | -54.7% |
| 净利率 | 6.1% | -62.0% |
| 营收同比 | -0.5% | 25.9% |
| 净利润同比 | -25.5% | 3.5% |
| 每股收益（稀释后） | $0.60 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $150.5M | $207.3M | ||
| Q3 25 | $154.0M | $159.9M | ||
| Q2 25 | $153.6M | $166.5M | ||
| Q1 25 | $142.8M | $139.3M | ||
| Q4 24 | $151.3M | $164.6M | ||
| Q3 24 | $155.2M | $139.5M | ||
| Q2 24 | $161.5M | $147.0M | ||
| Q1 24 | $150.3M | $108.8M |
| Q4 25 | $9.2M | $-128.6M | ||
| Q3 25 | $10.5M | $-180.4M | ||
| Q2 25 | $11.7M | $-115.0M | ||
| Q1 25 | $2.2M | $-151.1M | ||
| Q4 24 | $12.3M | $-133.2M | ||
| Q3 24 | $8.2M | $-133.5M | ||
| Q2 24 | $16.7M | $-131.6M | ||
| Q1 24 | $4.8M | $-170.7M |
| Q4 25 | 70.9% | — | ||
| Q3 25 | 68.4% | — | ||
| Q2 25 | 71.8% | — | ||
| Q1 25 | 66.3% | — | ||
| Q4 24 | 71.4% | — | ||
| Q3 24 | 70.5% | — | ||
| Q2 24 | 72.9% | — | ||
| Q1 24 | 67.5% | — |
| Q4 25 | 9.9% | -54.7% | ||
| Q3 25 | 10.9% | -106.9% | ||
| Q2 25 | 12.4% | -64.8% | ||
| Q1 25 | 3.6% | -102.6% | ||
| Q4 24 | 12.7% | -74.3% | ||
| Q3 24 | 14.8% | -94.6% | ||
| Q2 24 | 17.6% | -79.1% | ||
| Q1 24 | 7.0% | -151.9% |
| Q4 25 | 6.1% | -62.0% | ||
| Q3 25 | 6.8% | -112.8% | ||
| Q2 25 | 7.6% | -69.0% | ||
| Q1 25 | 1.6% | -108.5% | ||
| Q4 24 | 8.2% | -80.9% | ||
| Q3 24 | 5.3% | -95.7% | ||
| Q2 24 | 10.3% | -89.5% | ||
| Q1 24 | 3.2% | -156.8% |
| Q4 25 | $0.60 | $-1.28 | ||
| Q3 25 | $0.69 | $-1.81 | ||
| Q2 25 | $0.76 | $-1.17 | ||
| Q1 25 | $0.11 | $-1.57 | ||
| Q4 24 | $0.80 | $-1.34 | ||
| Q3 24 | $0.54 | $-1.40 | ||
| Q2 24 | $1.16 | $-1.52 | ||
| Q1 24 | $0.33 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.0M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $129.0M | $-80.0M |
| 总资产 | $458.0M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $58.0M | $421.0M | ||
| Q3 25 | $45.5M | $202.5M | ||
| Q2 25 | $31.2M | $176.3M | ||
| Q1 25 | $35.4M | $127.1M | ||
| Q4 24 | $38.8M | $174.0M | ||
| Q3 24 | $28.5M | $150.6M | ||
| Q2 24 | $77.1M | $480.7M | ||
| Q1 24 | $62.2M | $112.3M |
| Q4 25 | $129.0M | $-80.0M | ||
| Q3 25 | $121.5M | $9.2M | ||
| Q2 25 | $112.0M | $151.3M | ||
| Q1 25 | $105.8M | $144.2M | ||
| Q4 24 | $103.3M | $255.0M | ||
| Q3 24 | $90.4M | $346.8M | ||
| Q2 24 | $53.1M | $432.4M | ||
| Q1 24 | $37.2M | $140.3M |
| Q4 25 | $458.0M | $1.5B | ||
| Q3 25 | $436.5M | $1.2B | ||
| Q2 25 | $432.9M | $1.3B | ||
| Q1 25 | $417.7M | $1.3B | ||
| Q4 24 | $418.3M | $1.5B | ||
| Q3 24 | $390.8M | $1.5B | ||
| Q2 24 | $443.9M | $1.6B | ||
| Q1 24 | $428.2M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.1M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $16.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 10.6% | -48.6% |
| 资本支出强度资本支出/营收 | 2.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.07× | — |
| 过去12个月自由现金流最近4个季度 | $37.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $19.1M | $-99.8M | ||
| Q3 25 | $19.4M | $-91.4M | ||
| Q2 25 | $5.3M | $-108.3M | ||
| Q1 25 | $8.1M | $-166.5M | ||
| Q4 24 | $19.1M | $-79.3M | ||
| Q3 24 | $16.4M | $-67.0M | ||
| Q2 24 | $21.5M | $-77.0M | ||
| Q1 24 | $6.6M | $-190.7M |
| Q4 25 | $16.0M | $-100.8M | ||
| Q3 25 | $17.1M | $-92.7M | ||
| Q2 25 | $3.1M | $-110.7M | ||
| Q1 25 | $1.4M | $-167.8M | ||
| Q4 24 | $14.6M | $-79.5M | ||
| Q3 24 | $15.0M | $-68.6M | ||
| Q2 24 | $19.8M | $-79.0M | ||
| Q1 24 | $1.8M | $-193.9M |
| Q4 25 | 10.6% | -48.6% | ||
| Q3 25 | 11.1% | -58.0% | ||
| Q2 25 | 2.0% | -66.5% | ||
| Q1 25 | 1.0% | -120.5% | ||
| Q4 24 | 9.7% | -48.3% | ||
| Q3 24 | 9.6% | -49.2% | ||
| Q2 24 | 12.2% | -53.7% | ||
| Q1 24 | 1.2% | -178.2% |
| Q4 25 | 2.0% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 4.7% | 1.0% | ||
| Q4 24 | 2.9% | 0.1% | ||
| Q3 24 | 0.9% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% | ||
| Q1 24 | 3.2% | 3.0% |
| Q4 25 | 2.07× | — | ||
| Q3 25 | 1.84× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 3.60× | — | ||
| Q4 24 | 1.54× | — | ||
| Q3 24 | 2.00× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 1.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JILL
| Sales Channel Through Intermediary | $80.1M | 53% |
| Sales Channel Directly To Consumer | $70.5M | 47% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
